Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish | springermedicine.com

Springer Medicine

Top

Cardiovascular Toxicology

Published in:

01-01-2015

Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish

Authors: Jae-Yong Kim, Ki-Hoon Park, Jihoe Kim, Inho Choi, Kyung-Hyun Cho

Published in: Cardiovascular Toxicology | Issue 1/2015

Login to get access

Abstract

Safety concerns have been raised regarding the association of chronic consumption of artificial sweeteners (ASs) with metabolic disorders, especially in the heart and brain. There has been no information on the in vivo physiological effects of AS consumption in lipoprotein metabolism. High-dosage treatment (final 25, 50, and 100 mM) with AS (aspartame, acesulfame K, and saccharin) to human high-density lipoprotein (HDL) induced loss of antioxidant ability along with elevated atherogenic effects. Aspartame-treated HDL₃ (final 100 mM) almost all disappeared due to putative proteolytic degradation. Aspartame- and saccharin-treated HDL₃ showed more enhanced cholesteryl ester transfer activity, while their antioxidant ability was disappeared. Microinjection of the modified HDL₃ exacerbated the inflammatory death in zebrafish embryos in the presence of oxLDL. These results show that AS treatment impaired the beneficial functions of HDL, resulting in loss of antioxidant and anti-atherogenic activities. These results suggest that aspartame and saccharin could be toxic to the human circulation system as well as embryonic development via impairment of lipoprotein function.

1.

Bandyopadhyay, A., Ghoshal, S., & Mukherjee, A. (2008). Genotoxicity testing of low-calorie sweeteners: Aspartame, acesulfame-K, and saccharin. Drug and Chemical Toxicology, 31, 447–457.CrossRefPubMed

2.

Olney, J. W., Farber, N. B., Spitznagel, E., & Robins, L. N. (1996). Increasing brain tumor rates: Is there a link to aspartame? Journal of Neuropathology and Experimental Neurology, 55, 1115–1123.CrossRefPubMed

3.

Jang, W., Jeoung, N. H., & Cho, K. H. (2011). Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Molecules and Cells, 31, 461–470.CrossRefPubMedCentralPubMed

4.

Kim, J. Y., Seo, J., & Cho, K. H. (2011). Aspartame-fed zebrafish exhibit acute deaths with swimming defects and saccharin-fed zebrafish have elevation of cholesteryl ester transfer protein activity in hypercholesterolemia. Food and Chemical Toxicology, 49, 2899–2905.CrossRefPubMed

5.

Cho, K. H. (2009). Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: The functional role of apoC-III in rHDL. Molecules and Cells, 27, 291–297.CrossRefPubMed

6.

Rye, K. A., & Barter, P. J. (2008). Antiinflammatory actions of HDL: A new insight. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1890–1891.CrossRefPubMed

7.

Park, K. H., Jang, W., Kim, K. Y., Kim, J. R., & Cho, K. H. (2010). Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochemical and Biophysical Research Communications, 392, 295–300.CrossRefPubMed

8.

Roberts, H. J. (2003). Aspartame disease: An ignored epidemic. Ontario: Sunshine Sentinel Press.

9.

Selderslaghs, I. W., Blust, R., & Witters, H. E. (2012). Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. Reproductive Toxicology, 33, 142–154.CrossRefPubMed

10.

Selderslaghs, I. W., Van Rompay, A. R., De Coen, W., & Witters, H. E. (2009). Development of a screening assay to identify teratogenic and embryotoxic chemicals using the zebrafish embryo. Reproductive Toxicology, 28, 308–320.CrossRefPubMed

11.

Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955). The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation, 34, 1345–1353.CrossRefPubMedCentralPubMed

12.

Markwell, M. A., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978). A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Analytical Biochemistry, 87, 206–210.CrossRefPubMed

13.

Benzie, I. F., & Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. Analytical Biochemistry, 239, 70–76.CrossRefPubMed

14.

Eckerson, H. W., Wyte, C. M., & La Du, B. N. (1983). The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics, 35, 1126–1238.PubMedCentralPubMed

15.

Esterbauer, H., Striegl, G., Puhl, H., & Rotheneder, M. (1989). Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Research Communications, 6, 67–75.CrossRefPubMed

16.

Noble, R. P. (1968). Electrophoretic separation of plasma lipoproteins in agarose gel. Journal of Lipid Research, 9, 693–700.PubMed

17.

Park, K. H., Shin, D. G., Kim, J. R., & Cho, K. H. (2010). Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 65, 600–610.CrossRef

18.

Park, K. H., & Cho, K. H. (2011). High-density lipoprotein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosenescent properties with increased cholesterol influx. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 66, 511–520.CrossRef

19.

Owusu-Ansah, E., Yavari, A., Mandal, S., & Banerjee, U. (2008). Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nature Genetics, 40, 356–361.CrossRefPubMed

20.

Nusslein-Volhard, C., & Dahm, R. (2002). Zebrafish: A practical approach. New York: Oxford University Press.

21.

Park, K. H., & Cho, K. H. (2011). A zebrafish model for the rapid evaluation of pro-oxidative and inflammatory death by lipopolysaccharide, oxidized low-density lipoproteins, and glycated high-density lipoproteins. Fish & Shellfish Immunology, 31, 904–910.CrossRef

22.

Cho, K. H. (2009). Biomedicinal implications of high-density lipoprotein: Its composition, structure, functions, and clinical applications. BMB Rep., 42, 393–400.CrossRefPubMed

23.

Cho, K. H., Shin, D. G., Baek, S. H., & Kim, J. R. (2009). Myocardial infarction patients showed altered lipoprotein properties and functions when compared with stable angina pectoris patients. Experimental & Molecular Medicine, 41, 67–76.CrossRef

24.

Brown, B. E., Nobecourt, E., Zeng, J., Jenkins, A. J., Rye, K. A., & Davies, M. J. (2013). Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages. PLoS ONE, 31, e65430.CrossRef

25.

Kim, J., Park, H. H., Choi, I., Kim, Y. O., & Cho, K. H. (2010). Severely modified lipoprotein properties without a change in cholesteryl ester transfer protein activity in patients with acute renal failure secondary to Hantaan virus infection. BMB Reports, 43, 535–540.CrossRefPubMed

26.

Johnson, R. J., Segal, M. S., Sautin, Y., Nakagawa, T., Feig, D. I., Kang, D. H., et al. (2007). Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. American Journal of Clinical Nutrition, 86, 899–906.PubMed

27.

Hu, F. B., & Malik, V. S. (2010). Sugar-sweetened beverages and risk of obesity and type 2 diabetes: Epidemiologic evidence. Physiology & Behavior, 100, 47–54.CrossRef

28.

Gurney, J. G., Pogoda, J. M., Holly, E. A., Hecht, S. S., & Preston-Martin, S. (1997). Aspartame consumption in relation to childhood brain tumor risk: Results from a case–control study. Journal of the National Cancer Institute, 89, 1072–1074.CrossRefPubMed

29.

Soffritti, M., Belpoggi, F., Esposti, D. D., & Lambertini, L. (2005). Aspartame induces lymphomas and leukaemias in rats. European Journal of Oncology, 10, 107–116.

30.

Lim, U., Subar, A. F., Mouw, T., Hartge, P., Morton, L. M., Stolzenberg-Solomon, R., et al. (2006). Consumption of aspartame-containing beverages and incidence of hematopoietic and brain malignancies. Cancer Epidemiology, Biomarkers & Prevention, 15, 1654–1659.CrossRef

31.

Eshak, E. S., Iso, H., Kokubo, Y., Saito, I., Yamagishi, K., Inoue, M., et al. (2012). Soft drink intake in relation to incident ischemic heart disease, stroke, and stroke subtypes in Japanese men and women: The Japan Public Health Centre-based study cohort I. American Journal of Clinical Nutrition, 96, 1390–1397.CrossRefPubMed

32.

Burkhart, C. G. (2009). ‘Lone’ atrial fibrillation precipitated by monosodium glutamate and aspartame. International Journal of Cardiology, 137, 307–308.CrossRefPubMed

Title: Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish
Authors: Jae-Yong Kim
Ki-Hoon Park
Jihoe Kim
Inho Choi
Kyung-Hyun Cho
Publication date: 01-01-2015
Publisher: Springer US
Published in: Cardiovascular Toxicology / Issue 1/2015
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-014-9273-z

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties